Evidence map›Paper›PMID 34582005›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2021

UBE2S activates NF-κB signaling by binding with IκBα and promotes metastasis of lung adenocarcinoma cells.

Jhih-Yun Ho, Hsin-Ying Lu, Hsing-Hsien Cheng, Yu-Chieh Kuo, Yu-Lin Amy Lee, Chia-Hsiung Cheng

Abstract read
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. [Effect of CMTM6 on PD-L1 inBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2025
    Article
  6. Article
  7. [High expression of UBE2S promotes progression of hepatocellular carcinoma by increasing cancer cell stemness].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Jhih-Yun Ho *Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, 250 Wuxing Street, Taipei, 11031, Taiwan.
Hsin-Ying Lu *Division of Cardiovascular Surgery, Department of Surgery, Wan Fang Hospital, Taipei Medical University, 11031, Taipei, Taiwan.
Hsing-Hsien ChengDepartment of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, 250 Wuxing Street, Taipei, 11031, Taiwan.
Yu-Chieh KuoDepartment of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, 250 Wuxing Street, Taipei, 11031, Taiwan.
Yu-Lin Amy LeeDepartments of Medicine and Pediatrics, Duke University Hospital, Durham, NC, 27704, USA.
Chia-Hsiung ChengDepartment of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, 250 Wuxing Street, Taipei, 11031, Taiwan. chcheng@tmu.edu.tw.ORCID http://orcid.org/0000-0003-0307-9650
Taipei Medical University · TWDuke University Hospital · USWan Fang Hospital · TW

Funding

Taipei Medical University-Wan Fang Hospital 110TMU-WFH-21the Higher Education Sprout Project of the Ministry of Education (MOE), Taiwan DP2-109-21121-03-C-03-04the Minister of Science and Technology, Taiwan MOST107-2320-B-038-036 and MOST108-2320-B-038-014
6 · The paper itself

Abstract

purposeNuclear factor (NF)-κB signaling in cancer cells has been reported to be involved in tumorigenesis. Phosphorylation and degradation of inhibitor of NF-κBα (IκBα) is a canonical pathway of NF-κB signaling. Here, we aimed to identify and characterize noncanonical activation of NF-κB signaling by ubiquitin-conjugating enzyme E2S (UBE2S) in lung adenocarcinoma cells.

methodsTCGA and the Human Atlas Protein Database were used to analyze the survival rate of lung adenocarcinoma patients in conjunction with UBE2S expression. In addition, PC9, H460, H441 and A549 lung adenocarcinoma cells were used in this study. PC9 and H460 cells were selected for further analysis because they expressed different UBE2S protein levels. Specific IKK inhibitors, PS1145 and SC514, were used to assess IκBα phosphorylation. Western blot analysis was used to assess protein levels in PC9 and H460 cells. A scratch wound-healing assay was used to analyze the migrative abilities of PC9 and H460 cells. Overexpression and knockdown of UBE2S in H460 and PC9 cells were used to analyze their effects on downstream protein levels. Immunoprecipitation, immunofluorescent staining, glutathione S transferase (GST) pull-down and in vitro binding assays were used to analyze the interaction between UBE2S and IκBα. A luciferase assay was used to analyze activation of NF-κB signaling regulated by UBE2S. An in vivo zebrafish xenograft model was used to assess metastasis of PC9 cells regulated by UBE2S.

resultsWe found that UBE2S expression in lung adenocarcinoma patients was negatively related to survival rate. The protein level of UBE2S was higher in PC9 cells than in H460 cells, which was opposite to that observed for IκBα. PC9 cells showed a higher UBE2S expression and migrative ability than H460 cells. Phosphorylation of IκBα was not changed by treatment with the IKK-specific inhibitors PS1145 and SC514 in PC9 and H460 cells. Overexpression and knockdown of UBE2S in H460 and PC9 cells revealed that the protein levels of IκBα were inversely regulated. Immunoprecipitation, immunofluorescent staining, GST pull-down and in vitro binding assays revealed direct binding of UBE2S with IκBα. Nuclear P65 protein levels and luciferase assays showed that NF-κB signaling was regulated by UBE2S. The expression of epithelial-to-mesenchymal (EMT) markers and the migrative ability of lung adenocarcinoma cells were also regulated by UBE2S. A zebrafish xenograft tumor model showed a reduction in the metastasis of PC9 cells that was induced by UBE2S knockdown.

conclusionsHigher UBE2S expression in lung adenocarcinomas may lead to increased binding with IκBα to activate NF-κB signaling and promote adenocarcinoma cell metastasis. UBE2S may serve as a potential therapeutic target for lung adenocarcinomas.

Indexed as

Adenocarcinoma of LungAnimalsCell Line, TumorEnzyme ActivationEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansI-kappa B KinaseKaplan-Meier EstimateLung NeoplasmsModels, BiologicalNeoplasm MetastasisNF-kappa BNF-KappaB Inhibitor alphaProtein BindingProtein StabilityI-kappa B KinaseNF-kappa BNF-KappaB Inhibitor alphaTranscription Factor RelAUbe2S protein, humanUbiquitin-Conjugating EnzymesIκBαlung adenocarcinomametastasisNF-κBUBE2S

Identifiers

PMID34582005
PMCPMC12980711
OpenAlexW3153776870

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.